Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29319724 | 1.00 | NPC1 (0.34) | NPC1RAB9AKCNH2RPS6KB1LMNA | |
| SCHEMBL29319738 | 0.90 | GPR119 (0.38) | NPC1RAB9ALMNA | |
| SCHEMBL30995283 | 0.90 | GPR119 (0.38) | NPC1RAB9ALMNA | |
| SCHEMBL30995414 | 0.82 | DDB1 (0.33) | — | |
| SCHEMBL29319746 | 0.82 | DDB1 (0.33) | — | |
| SCHEMBL30849233 | 0.80 | SLC6A5 (0.35) | NPC1RAB9AKCNH2POLB | |
| SCHEMBL27213869 | 0.80 | SLC6A5 (0.35) | NPC1RAB9AKCNH2POLB | |
| SCHEMBL30849252 | 0.79 | PDE5A (0.32) | — | |
| SCHEMBL27213773 | 0.79 | PDE5A (0.32) | — | |
| SCHEMBL27392871 | 0.79 | PDE5A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |